RT Journal Article
SR Electronic
T1 SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.08.21267417
DO 10.1101/2021.12.08.21267417
A1 Cele, Sandile
A1 Jackson, Laurelle
A1 Khoury, David S.
A1 Khan, Khadija
A1 Moyo-Gwete, Thandeka
A1 Tegally, Houriiyah
A1 San, James Emmanuel
A1 Cromer, Deborah
A1 Scheepers, Cathrine
A1 Amoako, Daniel
A1 Karim, Farina
A1 Bernstein, Mallory
A1 Lustig, Gila
A1 Archary, Derseree
A1 Smith, Muneerah
A1 Ganga, Yashica
A1 Jule, Zesuliwe
A1 Reedoy, Kajal
A1 Hwa, Shi-Hsia
A1 Giandhari, Jennifer
A1 Blackburn, Jonathan M.
A1 Gosnell, Bernadett I.
A1 Karim, Salim S. Abdool
A1 Hanekom, Willem
A1 NGS-SA
A1 COMMIT-KZN Team
A1 von Gottberg, Anne
A1 Bhiman, Jinal
A1 Lessells, Richard J.
A1 Moosa, Mahomed-Yunus S.
A1 Davenport, Miles P.
A1 de Oliveira, Tulio
A1 Moore, Penny L.
A1 Sigal, Alex
YR 2021
UL http://medrxiv.org/content/early/2021/12/17/2021.12.08.21267417.abstract
AB The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may compromise vaccine effectiveness and the ability of antibodies triggered by previous infection to protect against re-infection (1). Here we investigated whether Omicron escapes antibody neutralization in South Africans, either previously SARS-CoV-2 infected or uninfected, who were vaccinated with Pfizer BNT162b2. We also investigated if Omicron requires the ACE2 receptor to infect cells. We isolated and sequence confirmed live Omicron virus from an infected person in South Africa and compared plasma neutralization of this virus relative to an ancestral SARS-CoV-2 strain with the D614G mutation, observing that Omicron still required ACE2 to infect. For neutralization, blood samples were taken soon after vaccination, so that vaccine elicited neutralization was close to peak. Neutralization capacity of the D614G virus was much higher in infected and vaccinated versus vaccinated only participants but both groups had 22-fold Omicron escape from vaccine elicited neutralization. Previously infected and vaccinated individuals had residual neutralization predicted to confer 73% protection from symptomatic Omicron infection, while those without previous infection were predicted to retain only about 35%. Both groups were predicted to have substantial protection from severe disease. These data support the notion that high neutralization capacity elicited by a combination of infection and vaccination, and possibly boosting, could maintain reasonable effectiveness against Omicron. A waning neutralization response is likely to decrease vaccine effectiveness below these estimates. However, since protection from severe disease requires lower neutralization levels and involves T cell immunity, such protection may be maintained.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), and South African Medical Research Council awards (AS, TdO, PLM). PLM is also supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the NRF (Grant No 9834). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Blood samples were obtained from hospitalized adults with PCR confirmed SARS-CoV-2 infection and/or vaccinated individuals who were enrolled in a prospective cohort study approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001275/2020). Use of residual swab sample was approved by the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref. M210752).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript